X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BIOCON LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BIOCON LTD GLENMARK PHARMA/
BIOCON LTD
 
P/E (TTM) x 19.8 92.2 21.4% View Chart
P/BV x 3.5 7.5 47.0% View Chart
Dividend Yield % 0.3 0.2 207.2%  

Financials

 GLENMARK PHARMA   BIOCON LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
BIOCON LTD
Mar-17
GLENMARK PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs9931,162 85.5%   
Low Rs729483 151.2%   
Sales per share (Unadj.) Rs325.5194.6 167.3%  
Earnings per share (Unadj.) Rs39.334.4 114.2%  
Cash flow per share (Unadj.) Rs48.748.3 100.8%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.1 191.0%  
Book value per share (Unadj.) Rs159.2241.9 65.8%  
Shares outstanding (eoy) m282.17200.00 141.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.2 62.6%   
Avg P/E ratio x21.923.9 91.7%  
P/CF ratio (eoy) x17.717.0 103.9%  
Price / Book Value ratio x5.43.4 159.1%  
Dividend payout %5.12.9 175.1%   
Avg Mkt Cap Rs m242,991164,440 147.8%   
No. of employees `00013.09.2 140.4%   
Total wages/salary Rs m16,4087,470 219.7%   
Avg. sales/employee Rs Th7,083.94,213.9 168.1%   
Avg. wages/employee Rs Th1,265.4809.0 156.4%   
Avg. net profit/employee Rs Th855.1745.2 114.7%   
INCOME DATA
Net Sales Rs m91,85738,911 236.1%  
Other income Rs m3741,571 23.8%   
Total revenues Rs m92,23040,482 227.8%   
Gross profit Rs m20,3679,795 207.9%  
Depreciation Rs m2,6442,772 95.4%   
Interest Rs m2,373260 912.8%   
Profit before tax Rs m15,7248,334 188.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,616 236.8%   
Profit after tax Rs m11,0886,881 161.1%  
Gross profit margin %22.225.2 88.1%  
Effective tax rate %24.319.4 125.5%   
Net profit margin %12.117.7 68.3%  
BALANCE SHEET DATA
Current assets Rs m68,74640,477 169.8%   
Current liabilities Rs m27,02716,783 161.0%   
Net working cap to sales %45.460.9 74.6%  
Current ratio x2.52.4 105.5%  
Inventory Days Days8560 142.6%  
Debtors Days Days9683 115.3%  
Net fixed assets Rs m24,13245,073 53.5%   
Share capital Rs m2821,000 28.2%   
"Free" reserves Rs m44,64347,377 94.2%   
Net worth Rs m44,92548,377 92.9%   
Long term debt Rs m45,36321,082 215.2%   
Total assets Rs m117,63993,942 125.2%  
Interest coverage x7.633.1 23.1%   
Debt to equity ratio x1.00.4 231.7%  
Sales to assets ratio x0.80.4 188.5%   
Return on assets %11.47.6 150.5%  
Return on equity %24.714.2 173.5%  
Return on capital %19.112.6 151.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15212,988 432.3%   
Fx outflow Rs m8,0847,899 102.3%   
Net fx Rs m48,0685,089 944.5%   
CASH FLOW
From Operations Rs m6,5746,400 102.7%  
From Investments Rs m-7,124-4,985 142.9%  
From Financial Activity Rs m5,432-1,775 -306.0%  
Net Cashflow Rs m1,992-473 -421.2%  

Share Holding

Indian Promoters % 48.3 40.4 119.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 6.9 8.4 82.1%  
FIIs % 34.4 10.7 321.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   56,727 109,995 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  FRESENIUS KABI ONCO.  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 19, 2018 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - FULFORD INDIA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS